Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
J Herrmann, D Lenihan, S Armenian… - European heart …, 2022 - academic.oup.com
Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …
Cardiotoxicity of anthracyclines
D Cardinale, F Iacopo, CM Cipolla - Frontiers in cardiovascular …, 2020 - frontiersin.org
Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …
[HTML][HTML] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G Curigliano, D Lenihan, M Fradley, S Ganatra… - Annals of …, 2020 - Elsevier
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed
world. Evidence increasingly shows that these conditions are interlinked through common …
world. Evidence increasingly shows that these conditions are interlinked through common …
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure …
R Pudil, C Mueller, J Čelutkienė… - European journal of …, 2020 - Wiley Online Library
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
V Quagliariello, M De Laurentiis, D Rea… - Cardiovascular …, 2021 - Springer
Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many
people perceive breast cancer to be the number one threat to women's health. CVD and …
people perceive breast cancer to be the number one threat to women's health. CVD and …
Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta …
Importance Echocardiographic left ventricular global longitudinal strain (GLS) detects early
subclinical ventricular dysfunction and can be used in patients receiving potentially …
subclinical ventricular dysfunction and can be used in patients receiving potentially …
Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association
The first classification on this topic categorized cardiomyopathies as heart muscle diseases
with dilated (DCM), hypertrophic, restrictive, arrhythmogenic right ventricular (ARVC), or …
with dilated (DCM), hypertrophic, restrictive, arrhythmogenic right ventricular (ARVC), or …
Cardiotoxicity of anticancer treatments: epidemiology, detection, and management
G Curigliano, D Cardinale, S Dent… - CA: a cancer journal …, 2016 - Wiley Online Library
Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …
morbidity and mortality in the industrialized world. Modern treatment strategies have led to …
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on …
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice …
College of Cardiology Foundation/American Heart Association Task Force on Practice …